Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months
First Sales Of Newly Approved Product Expected In Q1 2023
Executive Summary
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.
You may also be interested in...
Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.
Finance Watch: Sun Shines On Biotech Stocks As J.P. Morgan Ends
Public Company Edition: Also, Johnson & Johnson’s consumer health spin-out Kenvue filed paperwork to get the ball rolling on an initial public offering. In addition, Geron raised $198m and Madrigal accessed more than $300m after positive trial readouts, but layoffs were revealed by Editas, Elevation, Nabriva and others.
Bluebird’s Zynteglo Shows Long-Term Efficacy And Safety Amid US Commercialization Push
Data presented at ASH show patients maintaining transfusion independence for years after infusion, months after bluebird won FDA approval for the beta-thalassemia gene therapy.